Synarel Shortage: What Providers and Prescribers Need to Know in 2026

Synarel (nafarelin acetate) is not on the FDA's official drug shortage list as of 2026, but your patients are likely experiencing real access difficulties. As a brand-only specialty nasal spray with no US generic equivalent, Synarel simply isn't stocked at most community pharmacies — and when patients can't find it, they come back to you.

This guide is designed for OB/GYNs, reproductive endocrinologists, pediatric endocrinologists, and other prescribers who manage patients on Synarel. We'll cover the current access landscape, clinical alternatives, PA requirements, and how to streamline the process for your patients.

Understanding the Access Problem With Synarel

Synarel's access challenges are structural. The drug is manufactured exclusively by Pfizer (G.D. Searle LLC) with no FDA-approved generic. Retail pharmacies face a steep wholesale price on an infrequently requested product — so most don't stock it. The result is that most patients will need a specialty pharmacy to fill their prescription.

Internationally, the UK experienced a formal nafarelin shortage in late 2022, and Australia required special import approvals during the same period. While the US has not reached official shortage status, these supply chain events highlight the vulnerability of a single-manufacturer product.

Prior Authorization Requirements for Synarel

Virtually all commercial insurance plans and Medicaid managed care organizations require prior authorization (PA) for Synarel. Criteria vary by payer, but common PA requirements include:

For endometriosis:

Diagnosis confirmed by a gynecologist or reproductive endocrinologist

Step therapy: trial and inadequate response to an oral contraceptive or other first-line agent may be required before GnRH agonist approval

Patient must be 18 years of age or older

Total duration typically approved for 6 months (may be extended to 12 months on some plans with add-back therapy documentation)

For central precocious puberty (CPP):

Confirmed diagnosis by pubertal response to GnRH stimulation test or pubertal LH level

Bone age assessment supporting the diagnosis

Prescribed by or in consultation with a pediatric endocrinologist

Some payers also require ruling out pathological causes (e.g., intracranial abnormalities)

Clinical Alternatives When Synarel Is Unavailable

If a patient cannot access Synarel, the following alternatives should be considered based on indication:

Endometriosis alternatives:

Leuprolide depot (Lupron Depot 3.75 mg/month): GnRH agonist IM injection; most widely used alternative; monthly dosing improves adherence over daily nasal spray

Goserelin (Zoladex 3.6 mg monthly): Subcutaneous implant; clinically equivalent to Lupron for endometriosis

Elagolix (Orilissa 150 mg or 200 mg BID): Oral GnRH antagonist; no initial hormone flare; immediate hormonal suppression; not appropriate for patients with hepatic impairment or those on certain antiretrovirals

Central precocious puberty alternatives:

Leuprolide depot (Lupron Depot-PED): Monthly or 3-month IM injection; the standard of care for most CPP cases in the US; most evidence base

Triptorelin (Triptodur): 6-month IM injection for CPP; reduces injection frequency burden significantly

Histrelin (Supprelin LA): Annual subcutaneous implant in the upper arm; excellent for patients with compliance challenges; requires minor surgical procedure for placement and removal

Clinical Considerations When Transitioning Away From Synarel

When transitioning a patient from nafarelin nasal spray to a depot injectable or subcutaneous implant, consider the following:

Timing: Plan the injection to start when the last Synarel dose would have been — typically within 1–2 days of the last nasal spray dose. Avoid prolonged gaps in GnRH suppression, particularly for CPP patients.

Initial flare: GnRH agonist injectables (leuprolide, goserelin, triptorelin) will cause an initial hormone flare on first injection. Counsel patients and families accordingly.

Insurance re-authorization: Switching to a different drug may require a new PA. Submit the PA at the same time you decide to transition to avoid gaps in coverage.

How to Help Your Patients Find Synarel When They Need It

If you want to keep patients on Synarel rather than transitioning them, consider directing them to medfinder for providers. medfinder calls pharmacies on behalf of patients to find which ones can fill the prescription — eliminating the burden from your office staff and your patients.

You can also identify 1–2 specialty pharmacies in your area that reliably carry Synarel, and build them into your prescribing workflow. This eliminates repeated troubleshooting calls from patients who can't find it.

See our full provider guide to helping patients find Synarel in stock for more detailed workflow recommendations.